Inventor · disambiguated record
Takumi Kawabe
Also filed as: KAWABE TAKUMI
19 granted patents·6 pending applications·74 citations·filing 2000–2024
92Inventor score
Files withCANBAS CO LTD13TAKEDA PHARMACEUTICAL4GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION3KAWABE TAKUMI3HITACHI LTD1
Top patents by PatentIndex Score
25 records- 0188US7125842B2Anti-fungal compounds and methods of useCANBAS CO LTD·Filed 2004·Granted Oct 24, 2006·41 cites·61 claims
- 0284US11023404B2Daisy chain connection system and system control methodHITACHI LTD·Filed 2020·Granted Jun 1, 2021·2 cites·8 claims
- 0378US8084454B2Compounds with anti-cancer activityKAWABE TAKUMI·Filed 2008·Granted Dec 27, 2011·7 cites·95 claims
- 0477US6881575B1Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agentsCANBAS CO LTD·Filed 2000·Granted Apr 19, 2005·6 cites·5 claims
- 0576US7407985B2Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatmentsCANBAS CO LTD·Filed 2006·Granted Aug 5, 2008·2 cites·27 claims
- 0675US6995135B2Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatmentsCANBAS CO LTD·Filed 2003·Granted Feb 7, 2006·7 cites·40 claims
- 0770US7476657B2Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatmentsTAKEDA PHAMACEUTICAL COMPANY L·Filed 2005·Granted Jan 13, 2009·2 cites·12 claims
- 0869US2025092020A1IDO/TDO InhibitorGENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION·Filed 2024·Application pending·0 cites
- 0967US8415357B2Compounds with anti-cancer activityKAWABE TAKUMI·Filed 2010·Granted Apr 9, 2013·2 cites·104 claims
- 1064US7851592B2Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agentsCANBAS CO LTD·Filed 2004·Granted Dec 14, 2010·0 cites·19 claims
- 1163US7629364B2Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatmentsCANBAS CO LTD·Filed 2008·Granted Dec 8, 2009·0 cites·27 claims
- 1263US7358046B2Sensitivity test to predict efficacy of anti-cancer therapiesCANBAS CO LTD·Filed 2004·Granted Apr 15, 2008·2 cites·2 claims
- 1362US9221872B2Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulationsCANBAS CO LTD·Filed 2014·Granted Dec 29, 2015·1 cites·50 claims
- 1461US7479484B2Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activityTAKEDA PHARMACEUTICAL·Filed 2004·Granted Jan 20, 2009·1 cites·10 claims
- 1561US2009253635A1Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatmentsTAKEDA PHARMACEUTICAL·Filed 2008·Application pending·0 cites
- 1657US7652042B2Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatmentsCANBAS CO LTD·Filed 2008·Granted Jan 26, 2010·0 cites·33 claims
- 1757US2009192090A1Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activityTAKEDA PHARMACEUTICAL·Filed 2008·Application pending·0 cites
- 1853US12239714B2Phosphatidylserine-binding conjugatesCANBAS CO LTD·Filed 2022·Granted Mar 4, 2025·0 cites·22 claims
- 1953US12209079B2IDO/TDO inhibitorGENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION·Filed 2018·Granted Jan 28, 2025·0 cites·6 claims
- 2052US2022380305A1IDO/TDO InhibitorGENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION·Filed 2022·Application pending·0 cites
- 2149US9457757B2Interlocking structure, mounting member, and airbag deviceKAWABE TAKUMI·Filed 2013·Granted Oct 4, 2016·1 cites·14 claims
- 2247US7030111B2Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatmentsCANBAS CO LTD·Filed 2003·Granted Apr 18, 2006·0 cites·28 claims
- 2347US2010112089A1Peptide compound and use thereofTAKEDA PHARMACEUTICAL·Filed 2009·Application pending·0 cites
- 2443US10149887B2Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatmentCANBAS CO LTD·Filed 2016·Granted Dec 11, 2018·0 cites·35 claims
- 2528US2016061841A1Nrf2-based cancer treatment and detection methods and usesCANBAS CO LTD·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →